Haematologica

Article	Citations
A study of 28 pregnant women with sickle cell disease and COVID-19: elevated maternal and fetal morbidity rates.	140
<i>TCF3::HLF</i> acute lymphoblastic leukemia: still challenging to cure thirty years later	100
Non-tuberculous mycobacterial infections in hematology-oncology: we need to look harder	97
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival	97
A <i>Grammastola spatulata</i> mechanotoxin-4 (GsMTx4)-sensitive cation channel mediates increased cation permeability in human hereditary spherocytosis of multiple genetic etiologies	93
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment	82
Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy	74
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	72
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma	70
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	66
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia	64
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial	61
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	57
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy	55
The real world of acute lymphoblastic leukemia	54
Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome	53
B-cell lymphoblastic leukemia/lymphoma with mutated <i>IKZF1</i> N159Y: clinical and genetic features of an emerging entity	53
Images from the Haematologica Atlas of Hematologic Cytology: Sézary syndrome	51
Community respiratory viruses are generally well-tolerated in hematopoietic stem cell transplant recipients: a brief report from the TRANSPIRE study	51
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	48
Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition	48
Temporal changes in erythroid progenitors in critically ill patients: a prospective cohort study	47
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	47
Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?	46
Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies	45

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia	45
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis	43
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab oz	42
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia	42
Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation	40
Toward further excellence in <i>Haematologica</i>	40
Stage-specific dual function: EZH2 regulates human erythropoiesis by eliciting histone and non-histone methylation	38
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP	36
Improving the treatment of childhood acute lymphoblastic leukemia by optimizing the use of 70-year-old drugs	36
Inhibition of GPIb-α-mediated apoptosis signaling enables cold storage of platelets	36
Hepcidin regulation in Kenyan children with severe malaria and non-typhoidal <i>Salmonella</i> bacteremia	36
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	36
Unraveling the germline inheritance of the <i>JAK2</i>F556V gene mutation in familial thrombocythemia: a comprehensive analysis of 11 family members and potential implications for surveill	35
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	35
Patients with hypercortisolemic Cushing disease possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis	35
Red cell distribution width as a new prognostic biomarker in refractory chronic graft-versus-host disease	35
Therapeutic potential of fetal liver cell transplantation in hemophilia A mice	35
Cytomegalovirus-specific T cells following haploidentical transplants: reshaping a repertoire by half	35
Introduction to the Review Series on Myelodysplasia	34
Nearly 70 years later: the continued unraveling of Castleman disease	34
Iron- and erythropoietin-resistant anemia in a spontaneous breast cancer mouse model	33
40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies	33
The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements	32
Clinical phenotype of adult-onset systemic histiocytosis harboring <i>BRAF</i> in-frame deletions	32
Do we need more Genome Wide Association Studies?	32
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	32
A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis	32
t(15;17) in acute promyelocytc leukemia	31
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	31
<i>KDM4C</i> in germinal center lymphoma: a new piece of the epigenetic puzzle	31
Clinical impact of clonal hematopoiesis on severe COVID- 19 patients without canonical risk factors	31
<i>Erratum</i> to: Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes	31
Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia	29
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis	29
ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology	29
Spontaneous remission and loss of monosomy 7: a window of opportunity for young children with SAMD9L syndrome	28
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obs	27
Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant	27
Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma	27
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	27
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials	27
Oligosecretory Waldenström macroglobulinemia exhibits excellent treatment response and outcomes	27
Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma	26
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications	26
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration	26
Targeting TFH cells is a novel approach for donor-specific antibody desensitization of allograft candidates: an <i>in vitro</i> and <i>in vivo</i> study	25
Prognostic impact of <i>SF3B1</i> mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases	25
Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma	25
Eligibility criteria: too big, too small or just right?	25
High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies	24

Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy	24
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma	24
Low incidence of COVID-19 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon-1 activation?	24
The clonal hydra: neoantigen-specific T-cell response in germ cell tumors	24
Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia	23
Charting a path through resistance: HDAC inhibitors for TP53-mutated B-acute lymphoblastic leukemia	23
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	23
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research	23
CApSiZing T-cell acute lymphoblastic leukemia	23
The first human acute myeloid leukemia genome ever fully sequenced	23
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention	23
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome	22
Acute myeloid leukemia at first relapse: approaching the precipice	22
Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China	22
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia	22
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma	22
Lessons learned from therapy-related acute myeloid leukemia	21
The development of graft-<i>versus</i>-host disease prophylaxis	21
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	21
Terrific cells for SARS-CoV-2	21
Single cell analysis of the CD8<sup>+</sup> T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69<sup>-</sup> subset suggesti	21
Serological response following anti-SARS-CoV-2 vaccination in hematopoietic stem cell transplantation patients depends upon time from transplant, type of transplant and “booster” dose	21
<i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms	21
Does the world need germline editing for β-thalassemia?	20
Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”	20
Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis	20
Proteomics: a new era in pediatric acute myeloid leukemia research	20
Graft-<i>versus</i>-host disease in allogeneic transplantation: the good and the bad	20
Mature T-cell neoplasms and stem cell transplant: the never-ending story	19
The beginnings of molecular medicine	19
Images from the Haematologica Atlas of Hematologic Cytology: pure erythroid leukemia	19
Diagnosis of myelodysplastic syndromes: the classic and the novel	19
Challenging the status flow: how artificial intelligence is advancing diagnosis of myelodysplastic neoplasms	19
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	19
INTERFERing with the progression of T-cell acute lymphoblastic leukemia: a multifaceted therapy	19
Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation	19
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	19
PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease	19
Is it primary myelofibrosis or chronic megakaryocytic leukemia?	19
New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?	19
Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffus	19
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib	18
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia	18
Treatment with ibrutinib does not induce a <I>TP53</I> clonal evolution in chronic lymphocytic leukemia	18
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials	18
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience	18
Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an <i>ad hoc&l	18
<i>Erratum</i> to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies	18
Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein	18
The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma	18
Comprehensive <i>in silico</i> and functional studies for classification of <i>EPAS1/HIF2A</i> genetic variants identified in patients with erythrocytosis	18
Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients	18
Challenges in defining the immune microenvironment in T-cell lymphoma	18
Stem cell factor and erythropoietin-independent production of cultured reticulocytes	18
Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase <i>Erwinia chrysanthemi</i>	17
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β	17
Susceptibility to BK polyomavirus-associated hemorrhagic cystitis in children undergoing allogeneic transplant	17
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial	17
Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis	17
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	17
Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia	17
HES6: an emerging player in human hematopoiesis	16
Germline bi-allelic <i>SH2B3/LNK</i> alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorder	16
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study	16
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	16
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study	16
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	16
The GPIIb-IIIa defect of platelets in Glanzmann thrombasthenia	16
Myeloid cells from Langerhans cell histiocytosis patients exhibit increased vesicle trafficking and an altered secretome capable of activating NK cells	16
<i>TP53</i> DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification	16
Transforming growth factor-β signaling modifies the hematopoietic acute inflammatory response to drive bone marrow failure	16
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	16
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	15
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels	15
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy	15
Not all central nervous system lymphomas are created equal	15
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	15
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	15
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria	15
<i>CCL22</i> mutations in large granular lymphocytic leukemia	15

A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia	15
AURKA targeting: a NEAT approach to halt myeloma	14
Enforcement of stem-cell dormancy by nucleophosmin mutation is a critical determinant of unrestricted self-renewal during myeloid leukemogenesis	14
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from t	14
A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia	14
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia	14
Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience	14
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice	14
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib	14
Nucleotide sugars correlate with leukocyte telomere length as part of a dyskeratosis congenita metabolomic plasma signature	14
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease	14
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia	14
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38	14
Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsuficiency	14
Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia	14
The outcome and predictive model of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia from the Chinese Blood and Marrow Transplant Registry Group	13
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers	13
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety d	13
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy	13
Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes	13
Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis	13
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study	13
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	13
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	13
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm	13
Plasmablastic lymphoma: one or more tumors?	13
Differential activation of basal and IL-7-induced PI3K/Akt/mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia	13
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	13
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry	13
LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting	12
Translational readthrough at <i>F8</i> nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association	12
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma	12
Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity	12
Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia	12
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	12
The possible role of mutated endothelial cells in myeloproliferative neoplasms	12
Hodgkin/Reed-Sternberg cells induce GPNMB expression and release from macrophages to suppress T-cell responses to the Epstein-Barr virus-encoded LMP2A protein	12
Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma	12
Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma	12
A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations	12
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States	12
Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplant	12
How we manage a high D-dimer	12
Revumenib for patients with acute leukemia: a new tool for differentiation therapy	12
Increased frequency of clonal hematopoiesis of indeterminate potential in Bloom syndrome probands and carriers	12
Ethnic diversity in presentation and outcome of Waldenström macroglobulinemia and IgM monoclonal gammopathy of clinical significance in the United Kingdom	12
Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell	12
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	12
Overlapping DNA methylation changes in enhancers in clonal cytopenia of undetermined significance and myelodysplastic neoplasm patients with <i>TET2</i>, <i>IDH2</i>, or <i&	11
Interplay between circulating von Willebrand factor and neutrophils: implications for inflammation, neutrophil function, and von Willebrand factor clearance	11
Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets	11
Efficacy and feasibility of pharmacoscopy-guided treatment for acute myeloid leukemia patients who have exhausted all registered therapeutic options	11
Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Ped	11
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	11
Putting the brakes on cyclin C - a promising strategy to cure B-cell acute lymphoblastic leukemia?	11
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma	11
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial	11
A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options	11
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study	11
Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023	11
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies	11
The modern use of hydroxyurea for children with sickle cell anemia	11
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma	11
Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors	11
Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation	11
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy	11
Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma	10
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	10
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT	10
New insights into the generation and function of megakaryocytes in health and disease	10
Ubiquitin-proteasome pathway mediated regulation of Bcl-2 family: effects and therapeutic approaches	10
Crosstalk between β-catenin and WT1 signaling activity in acute myeloid leukemia	10
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial	10
Acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology in patients with severe disease: completing the landscape of thrombotic thrombocytopenic purpura	10
Infections in sickle cell disease	10
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis	10
A risk score based on real-world data to predict early death in acute promyelocytic leukemia	10
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial	10
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment	10
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma	10
Timely diagnosis and treatment of acute promyelocytic leukemia should be available to all	10
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission	10
hu128.1, a humanized antibody targeting transferrin receptor 1, blocks erythroleukemia growth in xenograft mouse models	10
Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study	10
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia	10
Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases	10
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial	10
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study	10
Maintenance therapy in acute myeloid leukemia: advances and controversies	10
Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders	10
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	10
Targeting a thrombopoietin-independent strategy in the discovery of a novel inducer of megakaryocytopoiesis, DMAG, for the treatment of thrombocytopenia	9
Transcriptome analysis in acute gastrointestinal graft-<i>versus</i> host disease reveals a unique signature in children and shared biology with pediatric inflammatory bowel disease	9
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot	9
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	9